



Cardiometabolic disease remains the leading global cause of morbidity and mortality, even as clinicians and patients work to control traditional risk factors. A new generation of tools—spanning molecular biology, imaging, data science, and targeted therapeutics—now makes genuinely individualized prevention and treatment possible. The challenge is no longer scientific imagination but operational execution.

This symposium summit brings together leaders from the provider, pharma, and payer communities to examine how precision medicine can be translated into routine cardiometabolic care—and what stands in the way. The program is built to make the interdependence of these groups explicit: the underlying biology, the clinical pathways, the payer incentives, and the practical steps required to deploy innovations at scale.

Through scientific talks, strategic perspectives, and moderated cross stake holder panels. The session will discuss the biological, clinical, economic, and operational opportunities for adoption.. The aim is to create shared context, clarify the real constraints, and identify realistic pathways toward individualized, biologically grounded care.

This working seminar is designed to catalyze collaboration among the stakeholders who must align if the promise of precision cardiometabolic care is to be realized.

Why Now

- ★ Growth in GLP-1s, SGLT2s, PCSK9s & anti-inflammatories
- ★ Rising payer pressure on cardiometabolic spend
- ★ Increasing demand for biologically interpretable AI/ML
- ★ New biobanking and multi-omic infrastructure
- ★ A shift toward value-based care and risk-bearing models

This event is not part of ACC.26, as planned by its Program Committee, and does not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.



Vascentis

Scan to register



www.vascentis.com | info@vascentis.com

The Next Era of Cardiometabolic Care



Precision, Prediction, Prevention

Aligning Incentives for Precision
Cardiometabolic Care

Date

Friday, March 27, 2:30 - 6 PM

Venue

The Riverfront Hotel
701 Convention Center Blvd, New Orleans

WELCOME AND FRAMING

🕒 5 min

Setting the purpose: crosstakeholder alignment for precision cardiometabolic care



Gregg W. Stone MD

Cardiologist, Mount Sinai Heart; Professor of Medicine and Population Health Science and Policy, Icahn School of Medicine at Mount Sinai

KEYNOTE ADDRESS

🕒 15 min

Health and Primary Prevention. Imaging: Behavior and Precision



Valentin Fuster, MD, PhD

President, Mount Sinai Fuster Heart Hospital; Physician-in-Chief, The Mount Sinai Hospital; General Director, CNIC, Madrid



🕒 10 min

Cardiovascular prevention: from population-based to individualized strategies



Ulf Hedin, MD, PhD

Vascular Surgeon-Scientist, Karolinska Institutet; Prof. of Vascular Surgery, Dept. of Molecular Medicine & Surgery, Karolinska Institutet



🕒 10 min

Pharmacologic Interventions for Primary and Secondary Prevention



Deepak L. Bhatt, MD, MPH

Director, Mount Sinai Fuster Heart Hospital; Professor of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai



🕒 10 min

Interventional Landscape for Secondary Prevention



Gregg W. Stone MD

Cardiologist, Mount Sinai Heart; Professor of Medicine and Population Health Science and Policy, Icahn School of Medicine at Mount Sinai



🕒 10 min

Considerations of equity and scale in precision medicine for CAD



Gemma A. Figtree, MB BS, DPhil (Oxon)

Cardiologist, Royal North Shore Hospital; Professor of Medicine, University of Sydney



🕒 10 min

Present Challenges and Opportunities in Management of Cardiometabolic Disease



Peter Libby, MD

Cardiovascular Medicine Specialist, Mass General Brigham Heart and Vascular Institute; Mallinckrodt Prof. of Medicine, Harvard Medical School

DISCUSSION PANEL #1

🕒 20 min

What's working and what's not? What don't we know?

Panelists: Ulf Hedin, Gregg Stone, Peter Libby, Gemma Figtree

Moderator: Valentin Fuster



🕒 15 min

Challenges and Opportunities for Individualized Quantitative Systems Pharmacology



Andrew J. Buckler, MS, PhD

Founder & CEO, Vascentis; Founder & Corp. Advisor, Elucid; Scientist & Entrepreneur in Cardiovascular Biology, AI/ML, and Systems Pharmacology



🕒 10 min

Use of National Registries as Evidence for Precision Cardiometabolic Care



David Erlinge, MD, PhD

Professor of Cardiology, Lund University; Head of Cardiology, Skåne University Hospital



🕒 10 min

Biobanking at Scale: Enabling Precision Biology



Clint L. Miller, PhD

Associate Professor of Genome Sciences, University of Virginia; Member, Center for Public Health Genomics; Cardiovascular Genomics Researcher



🕒 10 min

IP considerations for multi-scale modeling, biomarkers, and AI-driven therapeutics



Jeffrey J. Barclay, JD, MS

Principal, Fish & Richardson P.C.; Patent Strategist & Counsel specializing in global portfolio development, licensing & prosecution



🕒 10 min

Investment landscape for AI and precision cardiometabolic platforms



Claire Jin, MS

Vice President at JPMorgan Chase Bank

DISCUSSION PANEL #2

🕒 20 min

What Will It Take to Make Precision Cardiometabolic Care Real?

Aligning incentives, aggregating data, integrating into clinical workflows, intellectual properties and investment enablers.

Panelists: Claire Jin, Jeff Barclay, Gregg Stone, Clint Miller

Moderator: Andrew Buckler

CLOSING

🕒 5 min

Next Steps